{"product_id":"tides-usa-oligonucleotide-peptide-therapeutics-2025","title":"TIDES USA Oligonucleotide \u0026 Peptide Therapeutics 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: professionals in drug discovery, who focus on oligonucleotide, peptide, mRNA, and genome editing therapeutics\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eA translational, end-to-end program covering discovery, delivery, CMC, analytics, manufacturing, and clinical development for oligonucleotide and peptide drugs. Sessions convert cutting-edge science into practical playbooks for moving candidates efficiently from idea to IND and through the clinic.\u003c\/p\u003e\n\u003cp\u003eWhat You Will Learn\u003c\/p\u003e\n\u003cp\u003ePlatform selection \u0026amp; design: ASO\/siRNA\/miRNA\/mRNA\/saRNA vs. peptides\/peptidomimetics—chemistries, stability, and manufacturability\u003c\/p\u003e\n\u003cp\u003eDelivery strategies: LNPs, GALNAc, conjugates, depot and targeted systems; PK\/PD and biodistribution considerations\u003c\/p\u003e\n\u003cp\u003eCMC \u0026amp; analytics: impurity control, sequence confirmation, potency\/stability assays, comparability, and QbD\u003c\/p\u003e\n\u003cp\u003eProcess development \u0026amp; scale-up: solid-phase\/liquid-phase synthesis, hybrid approaches, purification and formulation\u003c\/p\u003e\n\u003cp\u003eRegulatory \u0026amp; quality: IND\/IMPD expectations, ICH alignment, control strategies, and lifecycle management\u003c\/p\u003e\n\u003cp\u003eNonclinical \u0026amp; clinical translation: models, safety\/pharm-tox, biomarkers, dose selection, trial design\u003c\/p\u003e\n\u003cp\u003eOperations: raw-material sourcing, supply chain resilience, technology transfer, and cost-of-goods levers\u003c\/p\u003e\n\u003cp\u003eData \u0026amp; digital: sequence optimization, structure prediction, in-silico off-target analysis, and AI\/automation in analytics\u003c\/p\u003e\n\u003cp\u003eEvent Details\u003c\/p\u003e\n\u003cp\u003eFormat: Plenary talks, parallel technical tracks, case studies, panels, posters, and exhibits\u003c\/p\u003e\n\u003cp\u003eStructure: Discovery\/design → Delivery\/PKPD → CMC\/analytics → Manufacturing\/scale-up → Clinical\/regulatory → Commercialization\u003c\/p\u003e\n\u003cp\u003eTakeaways: Checklists, templates, and benchmark metrics for immediate team adoption\u003c\/p\u003e\n\u003cp\u003eWho Should Attend\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D scientists, CMC and QA\/QC leaders, process\/analytical chemists, formulation and delivery engineers, clinical and regulatory teams, manufacturing\/operations managers, BD and strategy leaders, platform founders, and investors.\u003c\/p\u003e\n\u003cp\u003eWhy Attend\u003c\/p\u003e\n\u003cp\u003eReplace trial-and-error with validated development pathways for RNA and peptide modalities\u003c\/p\u003e\n\u003cp\u003eAnticipate regulatory and manufacturing pitfalls early to de-risk timelines and budgets\u003c\/p\u003e\n\u003cp\u003eBuild partnerships across discovery, CMC, and clinical teams to accelerate to proof-of-concept\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSchedule.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405798133956,"sku":null,"price":78.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/TIDES-USA-Oligonucleotide-Peptide-Therapeutics-2025.jpg?v=1784216298","url":"https:\/\/medicalcoursespro.com\/products\/tides-usa-oligonucleotide-peptide-therapeutics-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}